Tumor-Infiltrating Lymphocytes and CAR-T Therapy Rewrite Cancer Treatment: Three Scholars Win the Tang Prize in Biopharmaceutical Science
NQ Score
43/100
N1 Content Completeness
5
AI Summary (NQ-processed)
The 2026 Tang Prize in Biopharmaceutical Science was awarded to Steven A. Rosenberg, Michel Sadelain, and Carl H. June for their discovery and development of tumor-infiltrating lymphocytes and CAR-T therapy, which have revolutionized the treatment of blood cancers and solid tumors.
AI Analysis
Frequently Asked Questions
- Q: Who won the 2026 Tang Prize in Biopharmaceutical Science?
- A: Steven A. Rosenberg, Michel Sadelain, and Carl H. June shared the honor.
- Q: What does the Tang Prize in Biopharmaceutical Science recognize?
- A: It recognizes the discovery and development of tumor-infiltrating lymphocytes and CAR-T therapy, which have revolutionized the treatment of blood cancers and solid tumors.
- Q: What impact does this award have on the medical community?
- A: This award recognizes the importance of immunotherapy technologies, having a significant impact on the medical community.
- Q: What is CAR-T therapy?
- A: CAR-T therapy is an immunotherapy technology that modifies the patient's T cells to attack cancer cells.
- Q: What significance does this award have for the future of cancer treatment?
- A: This award may further promote the research of immunotherapy technologies, contributing to the progress of cancer treatment.